uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
18.05
+0.15 (0.84%)
Apr 28, 2026, 4:00 PM EDT - Market closed
uniQure Employees
uniQure had 221 employees as of December 31, 2025. The number of employees increased by 12 or 5.74% compared to the previous year.
Employees
221
Change (1Y)
12
Growth (1Y)
5.74%
Revenue / Employee
$72,842
Profits / Employee
-$900,321
Market Cap
1.14B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Xeris Biopharma Holdings | 435 |
| Pharming Group | 407 |
| UroGen Pharma | 291 |
| EyePoint | 214 |
| Omeros | 175 |
| Zenas BioPharma | 167 |
| Septerna | 130 |
| MoonLake Immunotherapeutics | 130 |
QURE News
- 23 hours ago - uniQure to Announce First Quarter 2026 Financial Results - GlobeNewsWire
- 18 days ago - UNIQURE DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. - GlobeNewsWire
- 26 days ago - UNIQURE DEADLINE APPROACHING: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. - GlobeNewsWire
- 4 weeks ago - QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data - PRNewsWire
- 7 weeks ago - This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down - Market Watch
- 7 weeks ago - Federal health officials attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment and accused it of lying - WSJ
- 7 weeks ago - FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease - CNBC
- 7 weeks ago - Sr. FDA official calls Uniqure's Huntington's disease treatment a failure - Reuters